OncoGenex Pharmaceuticals (OGXI) Completes Amendment to Phase 3 for Confirming Survival Benefit in Patients with First-Line Docetaxel for Metastatic Prostate Cancer
Tweet Send to a Friend
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company has reached an agreement with the U.S. Food and Drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
